Scaling Advanced Therapies: Dynamic Scheduling for Growth and Capacity

The Investment Summit returns to Phacilitate Advanced Therapies Week 2027

Alessandra Magnani, Head of Gene Therapy at L'Hopital San Joan Barcelona, speaks at ATE26

Aneta Tyszkiewicz, Director of Science & Regulatory at EFPIA, speaks at ATE26

Kieran Breen, Head of Research and Development at St Andrew's Healthcare at ATE26

Phacilitate Advanced Therapies Week 2027: Behind the Agenda

Phacilitate Advanced Therapies Week 2027 | Where the Industry Starts Its Year

Gunther Busam, VP at Orchard Therapeutics, speaks at ATE26

Laura Rodriguez from Invivo Partners speaks at ATE26

Mark Flower, VP of Business Development at AGC Biologics interviewed at #ATE26

Miguel Forte, CEO at Kiji Therapeutics speaks at #ATE26

Montse Daban, Director of Strategy and Global Partnerships at Biocat, during ATE26

Interview with Rahul Khetan Healthcare VC at UCB Ventures #ATE26

How to magnetize opportunities from the stage with Joanna Ghayad

Patient Acess in Advanced Therapies - ATE26

Manufacturing in Advanced Therapies - ATE26

Capital flow and investment - ATE26

China's Growth in Advanced Therapies - ATE26

Regulatory Harmony in Advanced Therapies - ATE26

The #ATE26 team's conference essentials!

Meet the team behind #ATE26 and what they're most looking forward to

Advanced Therapies Europe 2026 - Sponsor Onboarding

Europe's ATMP Roadmap: Can Europe Compete? | EU Biotech Act & Horizon Europe

Advanced Therapies Europe 2026 | Barcelona | Official Trailer

Is Advanced Therapies Europe Worth Attending? Hear From 2025 Attendees

Mentorship, power and the reality of inclusive leadership | #ATW26

Regulatory engagement strategies for early stage developers | #ATW26

She Leads Biotech Podcast Live | #ATW26

Geopolitics, policy, and the new global landscape for Advanced Therapies | #ATW26

Siren Biotechnology and the power of the crowd | #ATW26

Buildings or biotech Which comes first? | #ATW26

Bio2Bedside Podcast live - Leading Responsibly in Right-To-Try Legislation | #ATW26

The role of patient advocacy in shaping early clinical development | #ATW26

Closing Keynote: Turning broken systems into breakthroughs | #ATW26

Patient-centric by design: creating therapies with the patient in mind | #ATW26

Innovation Exchange | #ATW26

Developing unbiased assays to detect replication competent AAV in clinical vector products | #ATW26

Clinical Biomarkers of Durable Response to CiltacabtageneAutoleucelin Patients | #ATW26

Lessons from building a next generation translational center | #ATW26

Opening Plenary - 2025: What Worked. What Didn’t. What Comes Next | #ATW26

Tech Transfer and Manufacturing | #ATW26

How can AI accelerate R&D for CGT? | #ATW26

Forging effective partnerships across the advanced therapy ecosystem | #ATW26

Advancing targeted in vivo LNPs | #ATW26

The commercial blind spot - Bridging the business gap for scientific founders | #ATW26

Rethinking capital – Alternative funding models for biotech | #ATW26

Patient Spotlight | #ATW26

Investment Summit Opening Keynote | #ATW26

Inside the investor’s mind: What fundable companies look like in 2026 | #ATW26

Redefining representation — Inclusive leadership for the future of advanced therapies | #ATW26

WIAT Welcoming Address & Leadership and Life Lessons from the PCT | #ATW26

Clinical data generation in CGT strategy, operations and geography | #ATW26

Beyond the pipeline: Investing in the tools and tech powering CGT | #ATW26

Building a Collaborative Cell & Gene Therapy ecosystem in Saudi Arabia

Driving consistency, Yield, and Potency in Advanced Therapies with Predictive Analytics

Vitrafy: Cryopreservation as a Controlled, Intelligent Process

Innovation from Nucleus Biologics Enables Co-located Media & Buffer Manufacturing & Bioproduction

Clinical Trail Enablement - Demistifying Clinical Trials in Europe

Unlocking Scale: Rethinking Tools for the Next Era of Cell and Gene Therapy

The role of manufacturing in improving cell immunotherapies